Cargando…

Pharmacological treatments of presbyopia: a review of modern perspectives

INTRODUCTION: Presbyopia affects people from the 4(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaki...

Descripción completa

Detalles Bibliográficos
Autores principales: Renna, Antonio, Alió, Jorge Luciano, Vejarano, Luis Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294898/
https://www.ncbi.nlm.nih.gov/pubmed/28191476
http://dx.doi.org/10.1186/s40662-017-0068-8
_version_ 1782505328582066176
author Renna, Antonio
Alió, Jorge Luciano
Vejarano, Luis Felipe
author_facet Renna, Antonio
Alió, Jorge Luciano
Vejarano, Luis Felipe
author_sort Renna, Antonio
collection PubMed
description INTRODUCTION: Presbyopia affects people from the 4(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia. The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia. RESULTS: Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses. Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly. It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it. CONCLUSION: Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients. The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series. Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia.
format Online
Article
Text
id pubmed-5294898
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52948982017-02-10 Pharmacological treatments of presbyopia: a review of modern perspectives Renna, Antonio Alió, Jorge Luciano Vejarano, Luis Felipe Eye Vis (Lond) Review INTRODUCTION: Presbyopia affects people from the 4(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia. The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia. RESULTS: Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses. Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly. It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it. CONCLUSION: Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients. The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series. Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia. BioMed Central 2017-02-07 /pmc/articles/PMC5294898/ /pubmed/28191476 http://dx.doi.org/10.1186/s40662-017-0068-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Renna, Antonio
Alió, Jorge Luciano
Vejarano, Luis Felipe
Pharmacological treatments of presbyopia: a review of modern perspectives
title Pharmacological treatments of presbyopia: a review of modern perspectives
title_full Pharmacological treatments of presbyopia: a review of modern perspectives
title_fullStr Pharmacological treatments of presbyopia: a review of modern perspectives
title_full_unstemmed Pharmacological treatments of presbyopia: a review of modern perspectives
title_short Pharmacological treatments of presbyopia: a review of modern perspectives
title_sort pharmacological treatments of presbyopia: a review of modern perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294898/
https://www.ncbi.nlm.nih.gov/pubmed/28191476
http://dx.doi.org/10.1186/s40662-017-0068-8
work_keys_str_mv AT rennaantonio pharmacologicaltreatmentsofpresbyopiaareviewofmodernperspectives
AT aliojorgeluciano pharmacologicaltreatmentsofpresbyopiaareviewofmodernperspectives
AT vejaranoluisfelipe pharmacologicaltreatmentsofpresbyopiaareviewofmodernperspectives